Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion-Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series - Report - MDSpire
Advertisement
Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion-Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series
Clinical Report: Glutamatergic Augmentation in Treating Trauma-Related Disorders
Overview
This case series presents four patients with trauma-related disorders who experienced significant symptom improvement using a regimen of dextromethorphan, fluoxetine, and optional bupropion and piracetam. The findings suggest a potential for glutamatergic treatments to provide rapid relief in hard-to-treat cases, with improvements typically observed within days to weeks.
Background
Post-traumatic stress disorder (PTSD) and related trauma-spectrum disorders often respond poorly to traditional monoaminergic medications. There is a growing interest in glutamatergic treatments, which may enhance synaptic plasticity and disrupt maladaptive neural circuits. This case series explores the efficacy of a novel oral protocol involving dextromethorphan and other agents in patients with complex trauma-related conditions, highlighting the mechanisms by which these treatments may operate.
Data Highlights
No numerical or trial data were provided in the source material.
Key Findings
All four patients showed clinically meaningful symptom improvement within days to weeks. Notable reductions were observed in intrusive memories, rumination, somatic pain, and functional disability. No episodes of dissociation, hypertension, or mania were documented during follow-up, although structured screening for hypomania/mania and serotonergic toxicity was not performed. The treatment regimen included dextromethorphan, fluoxetine, and optional bupropion and/or piracetam. These findings are hypothesis-generating and suggest further investigation into oral NMDA–AMPA modulators for trauma-related conditions.
Clinical Implications
Clinicians may consider glutamatergic augmentation strategies for patients with treatment-resistant trauma-related disorders. The rapid symptom relief observed in this case series warrants further research into the efficacy and safety of such combinations in broader clinical settings, including structured screening for potential adverse effects.
Conclusion
This case series highlights the potential of glutamatergic treatments in managing trauma-related disorders, suggesting a need for further controlled studies to validate these findings and their implications for clinical practice.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
